Chondrocyte	B:C3271470
proliferation	I:C3271470
,	O
viability	B:C0007620
and	O
differentiation	B:C0007589
is	O
declined	O
following	O
administration	B:C1533734
of	O
methylphenidate	B:C0025810
utilized	O
for	O
the	O
treatment	B:C0087111
of	O
attention	B:C1263846
-	I:C1263846
deficit	I:C1263846
/	I:C1263846
hyperactivity	I:C1263846
disorder	I:C1263846
.	O

Methylphenidate	B:C1320172
(	I:C1320172
MPH	I:C1320172
)	I:C1320172
derivative	I:C1320172
drugs	B:C1254351
are	O
used	O
because	O
of	O
psychostimulants	B:C0304403
effects	O
on	O
attention	B:C1263846
-	I:C1263846
deficit	I:C1263846
hyperactivity	I:C1263846
disorder	I:C1263846
in	O
children	O
and	O
adults	O
.	O

As	O
far	O
as	O
we	O
know	O
,	O
toxic	O
or	O
anti-proliferative	B:C0243095
effects	I:C0243095
of	O
Methylphenidate	B:C0025810
against	O
cartilage	B:C0007301
tissue	I:C0007301
were	O
not	O
studied	O
in	O
the	O
literature	B:C0023866
.	O

The	O
present	O
study	B:C2603343
was	O
carried	O
out	O
to	O
investigate	O
the	O
possible	B:C0332149
effects	O
of	O
Methylphenidate	B:C0025810
on	O
the	O
proliferation	B:C3271470
,	O
viability	B:C0007620
and	O
differentiation	B:C0007589
of	O
primary	O
human	B:C0086418
chondrocytes	B:C0225369
,	O
in	O
vitro	O
.	O

Monolayer	O
primary	O
chondrocyte	B:C0225369
cultures	O
were	O
prepared	B:C4082130
using	O
osteochondral	B:C2937247
tissue	B:C0040300
obtained	O
from	O
patients	O
who	O
underwent	O
a	O
total	B:C0086511
knee	I:C0086511
prosthesis	I:C0086511
operation	I:C0086511
.	O

Stock	B:C0525069
solution	I:C0525069
of	O
Methylphenidate	B:C0025810
was	O
prepared	B:C4082130
and	O
aliquots	O
having	O
1-1000	O
ÂµM	O
concentrations	O
of	O
the	O
drug	O
was	O
composed	O
.	O

These	O
solutions	B:C0525069
were	O
applied	O
to	O
the	O
wells	B:C4283957
containing	O
cultured	B:C0225369
chondrocyte	I:C0225369
samples	O
within	O
the	O
well	B:C0180454
plates	I:C0180454
.	O

Control	O
groups	O
were	O
composed	O
of	O
pure	O
chondrocyte	B:C0225369
culture	O
and	O
no	B:C0243095
solution	I:C0243095
was	O
added	O
into	O
them	O
.	O

All	O
groups	O
were	O
evaluated	O
at	O
24	O
,	O
48	O
and	O
72	O
h	O
in	O
order	O
to	O
determine	O
the	O
possible	B:C0332149
negative	B:C0205160
effects	O
of	O
the	O
drug	B:C1254351
on	O
the	O
chondrocytes	B:C0225369
.	O

In	O
the	O
group	O
where	O
Methylphenidate	B:C0025810
was	O
applied	O
,	O
it	O
was	O
found	O
that	O
viability	B:C0007620
,	O
proliferation	B:C0596290
and	O
stage	B:C0080188
-	I:C0080188
specific	I:C0080188
embryonic	I:C0080188
antigen	I:C0080188
-	I:C0080188
1	I:C0080188
protein	B:C1171362
expression	I:C1171362
were	O
decreased	O
in	O
comparison	O
to	O
the	O
control	O
group	O
.	O

It	O
was	O
emphasized	O
that	O
clinicians	B:C0871685
should	O
not	O
disregard	O
the	O
fact	O
that	O
this	O
drug	B:C1254351
might	O
suppress	O
chondrocyte	B:C3271470
cell	I:C3271470
proliferation	I:C3271470
and	O
chondrogenic	B:C0007589
differentiation	I:C0007589
.	O

